Citeline logo with a tagline underneath that reads a Norstella company.
Contact Us
Reports & Guides
March 18, 2026

AI in Pharma 2026: From Insight to Execution in Clinical Trials

The AI market is projected to grow from $4.35 billion in 2025 to about $25.73 billion by 2030 for the pharmaceutical sector, driven by innovations in clinical trials, precision medicine, and commercial operations.

This white paper focuses on how AI is being used today: what makes it work in practice, and what sponsors should do next.

Citeline may contact you about relevant products, services, and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

サイトラインより、関連する製品・サービス・コンテンツに関する情報をお届けする場合があります。配信停止や受信内容の管理をご希望の場合は、プリファレンスセンターをご利用ください。

ご提供いただいた情報は、当社のプライバシー通知に基づき適切に取り扱います。


FAQ

AI is reshaping clinical trials by accelerating processes such as patient recruitment, site selection, and protocol optimization. It enables predictive and prescriptive analytics, helping sponsors forecast timelines, identify risks early, and design more efficient, patient-centric trials. These capabilities reduce costs and improve success rates.
AI-driven systems significantly reduce drug discovery timelines — from four to five years to as little as six to eight months — by analyzing vast datasets and predicting molecular interactions. AI also enables drug repurposing, personalized therapies, and operational excellence in clinical trials. These improvements enhance efficiency, lower costs, and improve patient outcomes.
Emerging trends include the integration of digital twins, edge AI, and quantum AI into clinical workflows. Digital twins simulate patient profiles to optimize treatment strategies, while edge AI enables real-time monitoring via wearables for decentralized trials. Quantum AI is being piloted for complex tasks like protein folding and toxicology prediction. These innovations promise faster, more personalized, and secure drug development.